Immunotherapy Focus Leverage ImmunityBio’s core expertise in activating innate and adaptive immunity to position complementary oncology partnerships, especially in cancers with immune evasion where their ANKTIVA and BCG-related programs may synergize with existing therapies.

Strategic Partnerships Explore co-development or licensing opportunities leveraging their recent asset acquisitions (BCG strain from Japan BCG Laboratory) and ongoing ASCO/ISPOR publications to accelerate joint clinical programs and expand regional commercialization.

Global Market Entry Capitalize on recent market entries such as Saudi Arabia launch of ANKTIVA to pursue regional expansion collaborations, distribution agreements, and reimbursement discussions in Middle East and North Africa where immunotherapy adoption is growing.

Economic Value Evidence Highlight early health economic data showing cost advantages for ANKTIVA plus BCG versus existing therapies, using these findings to support payer discussions and ROI-focused proposals for health systems and national payers.

Risk and Compliance Anticipate and address investor and regulatory concerns by offering robust data rooms and due diligence support related to SEC-related investigations and securities litigation, ensuring transparent communication with potential partners and clients.